Online inquiry

IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1745MR)

This product GTTS-WQ1745MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL2RA gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000417.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3559
UniProt ID P01589
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1745MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15582MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA UNII-FFX71LCS5T
GTTS-WQ8124MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HH1
GTTS-WQ3801MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ15866MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb5871
GTTS-WQ4615MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-986015
GTTS-WQ4328MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BIVV009
GTTS-WQ15576MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA UNII-FFX71LCS5T
GTTS-WQ2913MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG827
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW